Accessibility

Our global life sciences company brings diagnostic testing & drug development together.

We have deep neurodegenerative biomarker experience to power your decisions.

Biomarkers are at the heart of today’s drug development and the pursuit of medicines for neurodegenerative diseases. Labcorp have analyzed nearly 30,000 neurodegenerative clinical trial and study samples on the Quanterix™ platform and has expertise in running the following:

Biomarker Associated Diseases
NfL Neurodegeneration: MS, ALS, AD, PD, FTD (frontotemperal dementia), HAND (HIV associated neurocognitive disorder), COVID-19 associated neurological disorders, concussion/mTBI
GFAP Neurodegeneration: MS, AD, NMOSD (neuromyelitis optica spectrum disorder), COVID-19 associated neurological disorders, concussion/mTBI
p-tau181 AD
Total tau Tauopathies: AD, FTD with Parkinsons (PD), PSP (progressive supranuclear palsy), HAND, concussion/mTBI
Neuro 3-plex: Amyloid beta (1-42), Amyloid beta (1-40), total tau AD, HAND
Neuro 4-plex E: Amyloid beta (1-42), Amyloid beta (1-40), NF-L and GFAP AD
Neuro 4-plex A: NF-L, GFAP, Total Tau, UCH-L1 Concussion/mTBI
a-synuclein PD, AD
Amyloid beta (1-42) AD
p-tau231 AD
Cytokine 3-plex: IL-6, TNFa, IL-10 AD (inflammation)

Want to learn more about biomarker solutions?

Visit the biomarker solutions section on Covance by Labcorp to learn more about multi-disciplinary and integrated solutions to meet your biomarker strategy goals.